ISTO Technologies, Inc. George Dunbar, President & CEO

ISTO Technologies, Inc. (“ISTO” or the “Company”) is a leading regenerative medicine company focused on developing and selling novel orthobiologic products for spine, sports medicine and trauma. The Company’s current commercial orthobiologic portfolio is comprised of three related technologies targeting spinal fusion procedures and other orthopedic applications:

•  InQu® – a 510(k)-cleared biosynthetic bone graft substitute used to promote bone formation in spinal fusions and other orthopedic procedures
•  CellPoint – A state of the art closed loop system for point of care (intra-op) delivery of concentrated bone marrow aspirate (cBMA)
•  Influx – A premium line of trabecular bone grafts

In addition to its commercial products, the Company has two clinical-stage development programs.  These programs both utilize ISTO’s proprietary, highly scalable and cost-effective platform technology capable of growing living cartilage tissue outside the body, enabling potential off-the-shelf treatments for cartilage repair.  The leading product candidates under the cell-therapy platform are NuQu for the treatment of discogenic back pain and RevaFlex for articular knee cartilage repair and restoration